BioNxt Receives Positive International Examination Report From the European Patent Office for Broad Patent Application for Sublingual Delivery of Anticancer Drugs for the Treatment of Autoimmune Neurodegenerative Diseases
VANCOUVER, BC / ACCESSWIRE / September 9, 2024 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT) is pleased to report that the European Patent Office ("EPO") has issued a positive international examination report for the Company's comprehensive patent application for sublingual delivery of anticancer drug for the treatment of autoimmune neurodegenerative diseases. The Company expects the EU patent to be granted within eight weeks and to rapidly enter the national phase of the Patent Cooperation Treaty ("PCT") patent process with submissions planned for the US, Canada, China, Japan, Australia, and other jurisdictions.
BioNxt plans to continue development of and extend its patent portfolio regarding orally dispersible films ("ODFs") containing highly potent anticancer compounds for neurodegenerative diseases. The Company intends to file several related provisional patent applications in the EU with three to four patents expected to be on file in multiple major international jurisdictions by late 2025 to early 2026 with potential patent protection extending to 2045.
BioNxt's lead program is the development of a 100% owned and proprietary ODF Cladribine dosage form, directed at the multiple sclerosis ("MS") market. Cladribine tablets are currently approved for use in over 75 countries, including by the United States Food and Drug Administration ("FDA") and the European Medicines Agency ("EMA"), with 2023 annual sales in excess of one billion USD according to Merck KGaA. Cladribine tablets are approved for several indications, namely highly active forms of relapsing-remitting MS. MS represents the largest market segment for the sale of Cladribine with approximately 2.3 million people living with MS worldwide, with the highest prevalence in North America and Europe, noted by Atlas of MS. The global Multiple Sclerosis drug market is expected to top USD 41 billion by 2033 according to Market.us.
Further to the Company's MS program, BioNxt is pleased to announce that its second clinical indication using anticancer compounds in an ODF delivery system will be Myasthenia Gravis ("MG"). MG is an autoimmune and neuromuscular disease characterised by muscle weakness and fatigue. Similar to MS patients, MG patients commonly experience Dysphagia (difficulty swallowing), which is expected to yield a significant advantage to ODF drug products over conventional tablet forms. The global MG market is expected to reach USD 6.7 billion by 2032.
In general, the expectation of continued increasing prevalence of Central Nervous System ("CNS") pathologies will drive investment into new drugs and new drug delivery systems capable of targeting these diseases. The market size for drugs to treat CNS diseases is growing and expected to reach USD 238.8 billion by 2032 according to GMI Market Insights.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience accelerator focused on next-generation drug formulations and delivery systems, diagnostic screening tests, and new active pharmaceutical production and evaluation, including: precision transdermal and oral dissolvable drug formulations; rapid, low-cost infectious disease and oral health screening tests; and standardization and clinical evaluation of emerging active pharmaceutical ingredients for neurological applications. The Company has research and development operations in North America and Europe, with an operational focus in Germany, and is currently focused on regulatory approval and commercialization of medical products for European markets.
BioNxt Solutions Inc.
Wolfgang Probst, CEO and Director
Email: info@bionxt.com
Phone: +1 780-818-6422
Cautionary Statement Regarding "Forward-Looking" Information
Some of the statements contained in this news release are forward-looking statements and information within the meaning of applicable securities laws. Forward-looking statements and information can be identified by the use of words such as "expects", "intends", "is expected", "potential", "suggests" or variations of such words or phrases, or statements that certain actions, events or results "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking statements and information are not historical facts and are subject to a number of risks and uncertainties beyond the Company's control. Actual results and developments are likely to differ, and may differ materially, from those expressed or implied by the forward-looking statements contained in this news release. Accordingly, readers should not place undue reliance on forward-looking statements. The Company undertakes no obligation to update publicly or otherwise revise any forward-looking statements, except as may be required by law.
SOURCE: BioNxt Solutions Inc.
View the original press release on accesswire.com
BioNxt Solutions Inc.
Subscribe to releases from ACCESSWIRE
Subscribe to all the latest releases from ACCESSWIRE by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESSWIRE
Addressing Climate Change by Changing Our Food Systems14.1.2025 14:00:00 CET | Press release
WASHINGTON, D.C. / ACCESSWIRE / January 14, 2025 / The year 2024 was the hottest year on record. For the first time the average global temperature rose to 1.6C above preindustrial levels, exceeding the 1.5C vital to preventing accelerating climate change. The effects of climate change are now visible on every continent.Image: www.freepik.com Up to a third of global greenhouse gas production to date can be attributed to animal agriculture and food systems. Yet, most climate change solutions neglect the importance of food systems in climate change mitigation. In the article, ‘Solving Climate Change Requires Changing Our Food Systems,' published in leading scientific journal Oxford Open Climate Change, prominent scientists from around the world propose that the pressing nature of irreversible climate change requires rethinking our food systems. Lead researcher Dr Feigin and her co-authors assert that "we must undertake a global shift to a fundamentally plant-based diet and a gradual globa
The AI Gap: New Survey Reveals Enterprises Are Lagging in the High-Stakes AI Adoption Race14.1.2025 09:00:00 CET | Press release
Nearly 40% of Employees Say Their Organization Is Falling Behind Competitors Due to Slow Adoption NEW YORK, NY / ACCESSWIRE / January 14, 2025 / A striking new survey from Unily uncovers an alarming truth: despite the excitement around AI as a transformative force, many enterprises struggle to adopt the technology in meaningful ways. The result is a growing gap between AI "haves" and "have nots," where enterprises adopting AI tools for their people are making quicker gains than those without. Additionally, employees who are open to using AI tools increasingly want more exposure to them and may even choose employers who are early AI adopters over those who are slower to adapt. The differences between companies and employees that embrace AI and those that don't include a downstream impact on Organizational Velocity. Organizational Velocity is defined as the ability to make sharp pivots, accelerate decision-making, and eliminate operational friction necessary to harness AI's full potentia
Walkbase Launches Game-Changing Millimeter Wave Sensor Solution at NRF's Big Show 202513.1.2025 08:00:00 CET | Press release
New analytics technology set to provide crucial in-store metrics for retail media attribution. NEW YORK CITY, NEW YORK / ACCESSWIRE / January 13, 2025 / STRATACACHE company Walkbase, the leading in-store analytics solutions provider for retailers, today unveils its new millimeter wave sensor technology. The Walkbase Millimeter Wave Sensor Solution provides retailers and premises owners a powerful way to accurately measure in-store customer behavior without collecting or divulging the personally identifying information (PII) of customers.Walkbase Millimeter Wave Sensor Solution NRF attendees learning about Walkbase's Millimeter Wave Sensor Solution The Walkbase Millimeter Wave Sensor Solution will be on display, along with retail solutions from other members of the STRATACACHE family of technology companies including PRN and Scala, at NRF at booth 5213 (level 3). "For retailers looking to track shopper activity in their store, without the risk of collecting unauthorized data, the millim
AML Incubator Launches Compliance Solution for European MSBs and VASPs Facing MiCA Regulatory Challenges10.1.2025 10:45:00 CET | Press release
AML Incubator (AMLI), a leading compliance consultancy, has introduced a new service package to assist European Money Service Businesses (MSBs) and Virtual Asset Service Providers (VASPs) in establishing operations in Canada. The service is designed to help businesses manage complex regulatory challenges arising from the European Union's Markets in Crypto-Assets (MiCA) regulation. VANCOUVER, BC / ACCESSWIRE / January 10, 2025 / The MiCA regulations, part of the EU's digital finance package, imposes strict compliance rules for crypto-asset issuers and service providers. These include licensing, registration, and transparency requirements aimed at improving market stability and investor protection. While MiCA brings greater oversight to the industry, many small and mid-sized MSBs and VASPs are struggling to meet these new demands within the required timelines. As deadlines approach, businesses are exploring alternative jurisdictions that provide clearer regulatory pathways without sacrif
IXOPAY & Riskified Announce Partnership to Boost Fraud Prevention and Enhance Enterprise Payment Orchestration9.1.2025 00:00:00 CET | Press release
The partnership will help ecommerce customers securely expand their businesses by leveraging omnichannel payment orchestration with AI fraud detection LEHI, UT and NEW YORK, NY / ACCESSWIRE / January 9, 2025 / IXOPAY, a leading enterprise payment orchestration platform, and Riskified (NYSE:RSKD), a leader in ecommerce fraud and risk intelligence, today announced a strategic partnership to enhance payment security, reduce fraud challenges and increase payment operation resilience. As global payment ecosystems become more complex, so do the associated risks. IXOPAY and Riskified are teaming up to provide businesses with a seamless, secure and efficient way to enhance their payments orchestration and effectively repel fraud threats. IXOPAY + Riskified IXOPAY and Riskified partnership This partnership combines IXOPAY's payment orchestration, tokenization, and flexible payment optimization capabilities with Riskified's AI-powered fraud and risk intelligence platform. Businesses using this c
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom